Ballentine Partners LLC Purchases 741 Shares of Hologic, Inc. (NASDAQ:HOLX)

Ballentine Partners LLC increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 19.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,632 shares of the medical equipment provider’s stock after purchasing an additional 741 shares during the quarter. Ballentine Partners LLC’s holdings in Hologic were worth $377,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the company. Prentiss Smith & Co. Inc. grew its holdings in shares of Hologic by 0.3% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock valued at $3,967,000 after acquiring an additional 130 shares in the last quarter. Massmutual Trust Co. FSB ADV grew its stake in Hologic by 20.3% in the second quarter. Massmutual Trust Co. FSB ADV now owns 831 shares of the medical equipment provider’s stock valued at $62,000 after purchasing an additional 140 shares in the last quarter. Graypoint LLC grew its stake in shares of Hologic by 3.9% in the first quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock valued at $302,000 after buying an additional 147 shares in the last quarter. Wedmont Private Capital grew its stake in shares of Hologic by 3.7% in the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock valued at $361,000 after buying an additional 162 shares in the last quarter. Finally, Sequoia Financial Advisors LLC grew its stake in shares of Hologic by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock valued at $536,000 after buying an additional 165 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling

In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the transaction, the insider now owns 10,476 shares in the company, valued at approximately $858,927.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.75% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on HOLX. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Mizuho upped their price objective on Hologic from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, October 4th. Royal Bank of Canada reissued a “sector perform” rating and set a $82.00 target price on shares of Hologic in a report on Friday, August 16th. Stephens reissued an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research report on Tuesday, July 30th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a research report on Tuesday, October 15th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $87.50.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $80.46 on Tuesday. Hologic, Inc. has a one year low of $64.02 and a one year high of $84.67. The company has a market cap of $18.78 billion, a price-to-earnings ratio of 41.05, a PEG ratio of 2.96 and a beta of 0.98. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. The firm has a 50 day simple moving average of $80.91 and a 200 day simple moving average of $77.88.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period last year, the company earned $0.93 earnings per share. Research analysts predict that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.